Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011)

International Journal of Antimicrobial Agents
Helio S SaderRobert K Flamm

Abstract

Ceftaroline was tested against 1859 clinically significant Gram-positive organisms from uncommonly isolated species. The organisms (31 species/groups) were collected from 133 medical centres worldwide over a 4-year period (2008-2011). Coagulase-negative staphylococci were generally susceptible to ceftaroline, with MIC50 values (minimum inhibitory concentration required to inhibit 50% of the isolates) of 0.06-0.5mg/L. Ceftaroline was active against Micrococcus spp. [minimum inhibitory concentration required to inhibit 90% of the isolates (MIC90)=0.06 mg/L], but showed more limited potency versus some Corynebacterium spp. and Listeria monocytogenes isolates. Ceftaroline was active against all β-haemolytic streptococci and viridans group streptococcal species/groups listed, with MIC50 and MIC90 values ranging from ≤ 0.015 mg/L to 0.03 mg/L and from ≤ 0.015 mg/L to 0.5mg/L, respectively. Based on these in vitro findings, ceftaroline may have a potential role in the treatment of infections caused by these rarer species as guided by reference MIC test results.

References

Oct 23, 2002·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Marianne Hindsholm, Henrik C Schønheyder
Aug 3, 2007·International Journal of Antimicrobial Agents·A L CaseyT S J Elliott
Apr 22, 2011·The Journal of Antimicrobial Chemotherapy·Ian A CritchleyDirk A Thye
Apr 28, 2012·North American Journal of Medical Sciences·Alaa H Al-CharrakhRana H S Al-Rubaye
Aug 29, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas M FileGary E Stein
Aug 29, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David J FarrellRonald N Jones
Mar 13, 2013·Antimicrobial Agents and Chemotherapy·Cristina García-de-la-MàriaUNKNOWN Hospital Clinic Experimental Endocarditis Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.